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Abstract: Nanogold particles are commonly used in nanomedicine. We generated physical 
nanogold (pNG) conjugated with different ratios of epigallocatechin-3-gallate (EGCG) and 
evaluated its physicochemical properties, antioxidant activity, and cytotoxicity in vitro as well 
as anticancer activity in vivo. Results showed that the EGCG-pNG conjugates were successfully 
prepared at ratios between 23:1 and 23:5, with the percentage of EGCG content increasing with 
the EGCG:pNG ratio from 23:1 (2.0% ± 0.02%) to 23:5 (28% ± 0.3%). EGCG-pNG particles 
at ratios of 23:1 and 23:5 demonstrated significantly decreased size from 500 to 20 nm and 
decreasing zeta potentials of 21 mV to –22 mV , respectively. At a ratio of 23:2.5, the EGCG-
pNG particles (27% EGCG, 50 nm in size, zeta potential of –8 mV) showed longer EGCG 
activity half-life (110 days vs 5 hours), controlled release (2 hours vs 30 minutes), and higher 
antioxidant activity (four times), as well as inhibition of tumor cell growth, than controls. The 
present study indicated that EGCG-pNG possesses promising therapeutic potential, based on 
its strong free-radical scavenging and anticancer activities.
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Background
Nanomedicine involves the utilization of nanotechnology for the benefit of human 
health and well-being. The use of nanotechnology in various sectors of therapeutics 
has revolutionized the field of medicine. Metal nanoparticles are new-generation 
materials that are being widely investigated for biomedical and therapeutic applications, 
including use in diagnostics, therapeutics, and as biomedical tools for research. In the 
case of gold nanoparticles (AuNPs), their size, shape, surface chemistry, and optical 
properties are all properties that can be controlled. They also have unique and very 
exciting capabilities, such as comparable size with biomolecules and the ability to 
bind to various molecules, which make them potential candidates for chemical as 
well as biological applications, such as AuNP-based drug delivery, cell-specific 
targeting, and controlled drug release.1 By taking advantage of their optical-electronic 
properties, numerous proven applications for AuNPs have shown promise for use in 
medicinal applications, including plasmon-based labeling and imaging, optical and 
electrochemical sensing, diagnostics, and therapy for various diseases (eg, cancer).2
Many naturally occurring phenolic compounds/substances as well as biotechnological 
products are receiving continuous attention from the viewpoint of antioxidation and 
have been shown to be effective antioxidants in biological systems.3 Much of the 
cancer-chemopreventive properties of green tea are mediated by epigallocatechin-3-
gallate (EGCG), a phenolic compound that induces apoptosis and arrests cell growth.4 
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Green tea enhances humoral and cell-mediated immunity, 
decreases the risk of certain cancers, and has certain 
advantages in treating inflammatory disorders.5 EGCG and 
its derivatives are some of the most important candidates for 
the development of effective and nontoxic medicines with 
strong free-radical scavenging and antioxidant actions.6 Some 
studies have demonstrated that EGCG combined with metal 
ions such as Fe3+ or Mn2+ to form complexes by gallate ring 
may enhance biological activity.7,8
However, no studies have been conducted on EGCG-con-
jugated nanogold, with the exception of our previous study,9 
which reported that EGCG particles were physically attached 
onto the surface of physical nanogold (pNG) particles, 
confirmed by scanning electron microscopy. The anticancer 
activity of the EGCG-adsorbed pNG was investigated and 
confirmed to inhibit tumor cell growth by means of cell apop-
tosis. The mechanism by which EGCG-pNG mediates tumor 
apoptosis was discovered to be activation of the caspase 
cascade through the Bcl-family proteins in the mitochondrial 
pathway. Additionally, the mechanism by which tumors are 
suppressed by injecting EGCG-pNG directly into the tumor 
site is determined to be through downregulation of vascular 
endothelial growth factor, whereas that by oral administra-
tion of EGCG is through reversing immune suppression 
upon cancer progression. In this study, pNG conjugated with 
EGCG resulted in the development of therapeutically useful 
and stable EGCG-pNG. The properties and stability of these 
particles were evaluated, and their antioxidant and antitumor 
activity in vivo were determined.
Materials and methods
Chemicals and apparatus
The EGCG was purchased from Sinopharm Chemical 
Reagent (Taipei, Taiwan), 1.6 nm pNG was purchased 
from Gold NanoTech (Taipei, Taiwan) and a Panasonic 
NN-S563JF frequency-conversion microwave oven was pur-
chased from Panasonic (Tokyo, Japan). All other chemicals 
used were of analytical grade.
High-performance liquid chromatography 
conditions
Qualitative EGCG was analyzed by high-performance liquid 
chromatography (HPLC). A Waters (Milford, MA) HPLC 
system equipped with an automated gradient controller, 
510 pumps, U6K injector, 481 detector, 746 data module, and 
Waters µBondapak C18 column (3.9 × 300 mm) was used for 
the analysis. Elution was carried out at ambient temperature 
(25°C) using 30 mM NaH2PO4:acetonitrile (80:20) as a mobile 
phase at a flow rate of 1.0 mL/min. UV detection was carried 
out at 274 nm. Samples were prepared by centrifugation at 
14,000 rpm (Sigma 1–14; Sartorius, Goettingen, Germany) 
for 2 hours. Then, 50 µL of supernatant added to 50 µM 
pentoxifylline (as an internal standard) was used for HPLC 
analysis. All extracts were prepared in triplicate, and 
each extract was analyzed three times. The EGCG and 
pentoxifylline retention times were 10.7 and 16.9 minutes, 
respectively. The EGCG concentration was found to be linear 
over a range of 0.06–4 µg/mL. The correlation coefficient was 
0.9996. The lowest value of the standard curve (0.056 µg/mL) 
was taken as the limit of quantization. The recovery of 
EGCG from three concentrations (0.1, 1, and 4 µg/mL) was 
80.13% ± 5.14%, 87.37% ± 3.51%, and 89.25% ± 2.19%, 
respectively. The relative standard deviations of accuracy 
and precision for three different EGCG concentrations (0.1, 
1, and 4 µg/mL) were 5.38%, 2.99%, and 1.86% for intraday 
analysis and 4.58%, 3.03%, and 1.40% for interday analysis, 
respectively.
EGCG-pNG particle formulation, 
purification, and the ratio of EGCG 
contained in the particles
A total of 1 mL of 23-ppm EGCG in 200 mM glycine 
hydrochloride (HCl; pH 2.0) was mixed with 1 mL of 
final concentration 1.0, 1.25, 2.5, and 5.0 ppm 1.6-nm 
diameter pNGs in 1 M Tris-HCl (pH 8.5) and ultrasonicated 
for 5 minutes at room temperature for the preparation 
of EGCG-pNG. The EGCG-pNG samples were then 
centrifuged at 14,000 rpm for 2 hours. The nanoparticles 
were cleaned by centrifugation and resuspended in 
distilled water three times to remove the EGCG. The free 
EGCG was determined by the above HPLC method. The 
concentration of pNG was calculated based on ultraviolet-
visible spectrophotometer (DU-640; Beckman Coulter, 
Brea, CA) analysis, and ultraviolet-visible detection was 
carried out at 520 nm. The 5-ppm concentration of 1.6 nm 
pNG was used to make a standard curve. The concentration 
of pNG was calculated based on the data that 1.6 nm pNG 
has an absorption of 0.8 at 520 nm when the concentration 
is 5 × 1013 mL−1. We calculated the pNG concentration by 
following the formula: CpNG = 5 × 1013 mL−1 × A/0.8 (A is 
the absorption of the sample at 520 nm). Each sample was 
assayed in triplicate. The fraction of EGCG contained 
in the EGCG-pNG was calculated by dividing the total 
EGCG amount by the sum of the total pNG and EGCG 
amounts.
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EGCG-pNG particle properties
Nanoparticle size was characterized by photon correlation 
spectroscopy (Zetasizer Nano ZS; Malvern Instruments, 
Malvern, UK). All measurements were done at a wavelength 
of 633 nm at room temperature with an angle of detection 
of 173°. Raw data were subsequently correlated to mean 
hydrodynamic size by cumulant analysis (Z-average 
mean). The zeta potential of all nanoparticles was analyzed 
by laser Doppler anemometry (Zetasizer Nano ZS). All 
samples were run in triplicate, and the mean averages and 
standard deviations were calculated. Samples were also 
examined using a Philips (Amsterdam, Netherlands) CM10 
transmission electron microscope operating at an accelerating 
voltage of 80 kV. Images were recorded digitally with a 
Gatan (Munich, Germany) MultiScan 791 CCD camera using 
Gatan’s Digital Micrograph 3.1 software pack.
Stability of EGCG-pNG  
at various pH levels
A total of 1 mL of EGCG-pNG (23:2.5) was sealed in an 
ampoule and placed in a digitally controlled incubator to 
equilibrate at 40°C (Fisher Scientific, St Louis, MO). The 
pH of EGCG-pNG dispersion was adjusted using 0.04 M 
trisodium citrate and 0.04 M citric acid (pH 2.32, 2.77, 3.60, 
4.46, 5.67, and 6.12) using a calibrated pH meter (Delux pH 
Meter 101; Adarsh Scientific Industries, Haryana, India). 
To determine the dissociation of free EGCG, the samples 
were analyzed at predetermined days (0, 1, 3, and 7). The 
determination of the percentage of free EGCG was carried 
out by a previously determined validated HPLC method. 
Each sample was assayed in triplicate.
Half-lives (t½) were calculated for the percentage of 
EGCG-pNG remaining for all the data points from 0 to 
7 days, which followed zero-order kinetics. The dissociation 
rate constant (k) was calculated by the slope, and the 
following equation was used to calculate the half-life: 
k = 0.693t½.
In vitro release test
In vitro release of EGCG from the EGCG-AuNPs (23:2.5) 
was determined using a dialysis device with a 100 KDa 
molecular weight cut-off in 150 mL of HCl solution (pH 1.2) 
at 36°C following the method published previously. An 
accurately measured amount of various particle formula-
tions was transferred to the dialysis bag and placed in a 
receiving compartment containing 120 mL HCl solution 
(pH 1.2). Control bags were prepared and tested in parallel. 
Each control bag contained 0.1 mg EGCG. The two ends of 
the dialysis bag were tightly bound with thread. The bags 
were hung inside a conical flask with the help of a glass rod 
so that the portion of the dialysis bag with the formulation 
dipped into the HCl solution. The flask was kept on a mag-
netic stirrer, and stirring was maintained at 100 rpm at 36°C 
with a thermostatic control. At predetermined time intervals, 
the release medium was withdrawn for analysis. The EGCG 
release by the particles was calculated by subtracting the 
initial amount of EGCG in the particles from the amount at 
the time of release.
Determination of the antioxidant activity 
of EGCG:pNG at a ratio of 23:2.5
Superoxide radicals6 were generated in 3 mL Tris-HCl buffer 
(16 mM, pH 8.0), which contained 78 µM NADH (reduced 
form), 50 µM nitroblue tetrazolium, and 10 µM phenazin 
methosulfate as well as 2 mL−1 of EGCG (23 ppm), pNG 
(2.5 ppm), EGCG-pNG (23:2.5 ppm), or α-tocopherol 
(vitamin E, 400 IU) as a control. The color reaction generated 
by superoxide radicals and nitroblue tetrazolium was detected 
by monitoring the absorbance at 560 nm. In the essential 
control, NADH was substituted with Tris-HCl buffer.
Hydroxyl radicals were generated in sodium phosphate 
buffer (150 mM, pH 7.4), which contained 0.15 mM FeSO4-
EDTA, 2 mM sodium salicylate, and 6 mM H2O2 as well as 
2 mL–1 of EGCG (23 ppm), pNG (2.5 ppm), EGCG-pNG 
(23:2.5 ppm), or vitamin E (400 IU) as a control. In the 
essential control, sodium phosphate buffer replaced H2O2. 
The solutions were incubated at 37°C for 1 hour and detected 
by monitoring the absorbance at 510 nm.
Effects of EGCG-pNG (23:2.5 ppm) on H2O2-induced 
hemolysis of rat erythrocytes and lipid peroxidation in 
rat liver microsomes were evaluated. Erythrocytes were 
separated by centrifugation from blood samples of male 
Wistar rats and resuspended in physiological saline to a final 
concentration of 0.5%. A total of 2 mL of reacting solution, 
which contained 1 mL erythrocyte suspension and 100 mM 
H2O2 as well as 2 mL–1 of EGCG (23 ppm), pNG (2.5 ppm), 
EGCG-pNGs (23:2.5 ppm), or vitamin E (400 IU) as a 
control, was incubated at 37°C for 1 hour, diluted with four 
volumes of physiological saline, and centrifuged at 1000 × g 
for 10 minutes. The supernatant was assayed by monitoring 
its absorbance at 414 nm. The essential control contained 
only the erythrocyte suspension in 2 mL of solution.
The percentage of antioxidant activity in the samples 
and the relative time of vitamin E antioxidant activity were 
evaluated according to the following formula: inhibition 
rate (%) = (A0 − A)/(A0 − Ae) × 100%, relative to vitamin E 
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antioxidant activity = S(IR%)/E(IR%); where A0 is the absorbance 
of the free-radical generation system, A is the absorbance of 
the test sample, Ae is the absorbance of the essential control, 
S(IR%) is the test sample inhibition rate (%), and E(IR%) is the 
vitamin E inhibition rate (%).
In vitro antitumor study
For cell-viability analysis, 1.5 × 104 cells resuspended in 
100 mL–1 medium were plated into each well of a 96-well 
plate for 24 hours. The cells were then treated with different 
concentrations of native EGCG (11.5 and 23 ppm), pNG 
(1 and 2.5 ppm), or EGCG-pNG (23:1 and 23:2.5 ppm) for 
24 and 48 hours. Cell proliferation was monitored using 
the CellTiter 96 AQueous One Solution Assay (Promega, 
Madison, WI) and performed according to the manufacturer’s 
instructions. Briefly, after treatment, 20 mL−1 of the combined 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) and 
phenazine methosulfate solution was added into the wells 
containing 100 mL−1 of culture medium and incubated for 
40 minutes at 37°C in a humidified 5% CO2 atmosphere. The 
absorbance at 490 nm was recorded using an enzyme-linked 
immunosorbent assay plate reader.
Cell viability was calculated using the following formula: 
cell viability (%) = (Abs of treated cells − Abs of free medium 
with EGCG)/(Abs of control untreated cells − Abs of free 
medium alone) × 100. The viability of cells left untreated 
was normalized to 100%. Six experimental sets were carried 
out, and each set was performed in triplicate.
Tumor model and experiment protocol
Female C3H/He mice aged 6–8 weeks were housed in a 
climate-controlled room (24°C, 50% ± 10% relative humidity, 
12-hour-light/12-hour-dark cycle, autoclaved bedding) with 
food (Labdiet 5001; Purina, St. Louis, MO) and water ad 
libitum. The Institutional Animal Care and Use Committee 
of the National Defense Medical Center in Taipei approved 
all experiments, and all animal work conformed to their 
guidelines for the humane care of animals. MBT-2 tumor cells 
(5 × 105) in a volume of 50 µL were injected subcutaneously 
into the right dorsal flank of the mice. Following inoculation 
with tumor cells or phosphate-buffered saline, body mass, 
food intake, and tumor size were measured four times 
weekly. Tumor growth was assessed by the measurement 
of two bisecting diameters in each tumor using calipers, 
and the tumor volume was calculated using the following 
equation: tumor volume (mm3) = width × length2/2. Tumor 
volumes after treatment were divided by volumes before 
chemotherapy and are expressed as tumor-volume-reduction 
ratios (TVRs).10 During the exponential growth phase, the 
tumor-volume-doubling time (Td) was calculated using the 
following formula11: Td = t × [log 2/(log Vb – log Va)], 
where Va is tumor volume at initial and Vb that at t days 
after Va.
Experiments were designed to test the drug (2 mg/mice 
EGCG or 2 mg/mice EGCG-pNG [23:2.5]) effects. Drugs 
were administered orally every other day before MBT-2 cell 
implantation, whereas in the treatment group administration 
started at 14 days after tumor implantation with a palpable 
nodule.
Statistical analysis
Data were expressed as the mean ± standard error of the 
mean. Statistical differences were assessed with the Student’s 
t-test. Statistical significance was set at P , 0.05.
Results and discussion
Evaluation of EGCG-loaded pNG
In this work, pNG particles were characterized via surface 
plasmon resonance at ∼512 nm in the ultraviolet-visible 
spectrum, which confirmed the formation of spheroid 
nanogold in solution. This was further confirmed by 
transmission electron microscope analysis indicating that 
96% of the nanogold particles had an approximate size of 
1.6 nm with a nearly uniform size distribution (Figure 1). 
After the successful synthesis of stable pNG, we selected 
EGCG for loading on synthesized pNG for drug delivery 
to tumor cells. Percentage loading of EGCG on pNG 
was determined based on EGCG content in the EGCG-
pNG particles, and the percentage of EGCG content was 
observed to have increased with an increasing EGCG:pNG 
ratio from 23:1 (2.0% ± 0.02%) to 23:5 (28% ± 0.3%) 
(Figure 2). Figure 2 shows that changes in the EGCG:pNG 
ratio altered the effective diameter and zeta potential of the 
conjugate particles; particle size and zeta potential decreased 
significantly with increasing EGCG:pNG ratios from 23:1 to 
23:5. Freshly prepared EGCG-pNG at a ratio of 23:1 were 
around 500 nm in size and had a zeta potential of 21 mV. 
The EGCG-pNG particles at a ratio of 23:2.5 contained 27% 
EGCG conjugate, were around 50 nm in size, and had a zeta 
potential of –8 mV; these particles were used for further 
study. In our previous report,9 EGCG particles were shown 
to be physically attached to the surface of pNG particles. 
In general, particle aggregation is less likely to occur for 
charged particles with an optimum zeta potential (±30 mV) 
due to electrostatic repulsion.12
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The size of nanoparticles used in a drug-delivery system 
should be large enough to prevent their rapid leakage into 
blood capillaries but small enough to escape capture by 
fixed macrophages that are lodged in the reticuloendothelial 
system, such as the liver and spleen. The size of the sinusoid 
in the spleen and fenestra of Kupffer cells in the liver 
  varies from 150 to 200 nm,13 and the size of gap junctions 
between endothelial cells of the leaky tumor vasculature 
may vary from 50 to 600 nm.14 Sonavane and colleagues 
also reported 15- to 50-nm AuNPs widespread in organs of 
mice through intravenous administration.15 Consequently, 
EGCG-pNG nanoparticles up to 50 nm in size should be 
able to reach tumor tissues by passing through these two 
vascular structures.
Stability over wide range  
of pH conditions
For varied therapeutic and biomedical applications, we 
performed stability analysis of EGCG-pNG (23:2.5) by 
monitoring EGCG by HPLC over a reasonable period of 
time and under pH conditions ranging from 2.32 to 6.12. 
Figure 3 shows the dissociation patterns of EGCG from 
EGCG-pNG (23/2.5) after incubation at varied pH at 40°C 
for 7 days. The results indicated that EGCG-pNG (23:2.5) 
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Figure 1 Transmission electron microscopy analysis of pNG particles. 
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graph generated by photon correlation spectroscopy. 
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Figure 2 The characteristics of EGCG-pNG particles show the percentage of EGCG capped on pNGs (Ο), particle size (◊), and zeta potential () at different ratios of 
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was easily dissociated into EGCG at pH 6.12 and 5.67. 
Based on the slope of the plot, the k and t½ of EGCG dis-
sociation from EGCG-pNG (23:2.5) were calculated. The 
k and t½ for pH 2.32, 2.77, 3.60, 4.46, 5.67, and 6.12 were 
0.0118, 0.0097, 0.0062, 0.018, 0.4553, and 1.7109 (1/day) 
and 58.66, 71.4, 110.95, 38.43, 1.52, and 0.41 (day), 
respectively. Such significant changes at a pH . 4 indi-
cated a greater instability of EGCG-pNG compared to 
borohydrate or citrate-reduced pNG aggregates.16 In our 
study, nanogold significantly increased the stability of 
EGCG with a t½ of 110 days compared to EGCG alone at 
4–5 hours; similar results were reported by Chen et al.17 
However, EGCG-pNG (23:2.5) particles were highly stable 
over a reasonable period of time at a pH , 4 (Figure 3B). 
EGCG-pNG was able to stably endure acidic conditions, 
which may be suitable to prevent gastric acid decomposing 
the EGCG, because pH values of 1.7 have been measured 
following fasting, and duodenal pH as high as 6.1 has been 
reported.18,19
The EGCG-release profiles  
of EGCG-pNG
EGCG release was investigated by studying release of 
encapsulated EGCG from EGCG-pNG (23:2.5) and 
comparing it with that of free EGCG. Figure 3C illustrates 
the release profile of EGCG, indicating a prolonged retention 
time for EGCG-pNG (23:2.5) particles as compared to free 
EGCG. The initial burst release (36.2% at 0.5 hours) of 
EGCG-pNG (23:2.5) particles was followed by a continued 
and controlled release phase of 101.5% at 2 hours.
Antioxidant activities
Figure 4 shows the superoxide radical scavenging effect, 
hydroxyl radical effect, and the effects of EGCG-pNG 
(23:2.5 ppm) on H2O2-induced hemolysis of rat erythrocytes 
and lipid peroxidation in rat liver microsomes. The EGCG, 
pNG, and EGCG-pNG (23:2.5 ppm) conjugates showed 
significant superoxide radical scavenging activity compared 
to vitamin E alone (Figure 4). EGCG, a good antioxidant 
for radical-initiated peroxidation of rat liver microsomes, 
has been noted by Cai et al.3 Also, Dai et al demonstrated 
that the mixture of the green tea polyphenol, vitamin E, and 
vitamin C can act synergistically to protect against lipid 
peroxidation.6 In the process of H2O2-induced erythrocyte 
hemolysis, H2O2 reacts with Fe2+ in erythrocytes to form 
hydroxyl free radicals, which induces substantial hemolysis. 
As such, the results of this erythrocyte hemolysis experi-
ment were consistent with that of the hydroxyl free-radical 
scavenging experiment. Lipid peroxidation is a complex 
process. It involves the formation and propagation of lipid 
peroxide and the eventual destruction of membrane lipids, 
producing breakdown products such as malondialdehyde in 
microsomes. In our study, we adopted the Fe2+/vitamin E 
system to induce the production of microsomal peroxyl 
radicals. EGCG-pNG particles demonstrated the strongest 
ability (about fourfold greater than native cells) to scavenge 
lipid peroxyl radicals.
In vitro antitumor effect of EGCG-pNG
In order to demonstrate the antitumor effect of the EGCG/
pNG (23:2.5 ppm) conjugates in vitro, we performed 
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cytotoxicity studies of native EGCG (11.5 and 23 ppm), pNG 
(1 and 2.5 ppm), and EGCG/pNG (23:1 and 23:2.5 ppm) on 
MBT-2 cells using an in vitro MTS assay method. At the 
end of 24 and 48 hours, we observed that native EGCG, 
pNG, and EGCG/pNG conjugates decreased cell viability 
(Figure 5). We first examined whether pNG and EGCG 
had any effect on MBT-2 proliferation. Compared at 24 
and 48 hours, a slight concentration-dependent increase 
in the cytotoxicity of pNG alone was observed, as well 
as a significant concentration-dependent increase in the 
cytotoxicity of EGCG. Importantly, where proliferation 
inhibition was increased with increasing concentrations of 
pNG, after 48 hours pNG was less toxic than at 24 hours. At 
the end of 48 hours, the decrease in cell viability with native 
EGCG and pNG alone in the concentration range studied 
was found to be 25%–12.5% and 85%–80%, respectively. It 
was interesting to note a significantly increased cytotoxicity 
for the varied ratios of EGCG-pNG particles as compared 
to native EGCG or pNG alone (P , 0.0001) (Figure 5). 
Venkatpurwar et al prepared AuNPs capped with porphyran, 
and these particles exhibited enhanced cytotoxicity in human 
glioma cells (LN-229), as compared with native porphyran.20 
They also reported on AuNPs utilized as carriers for the 
delivery of the anticancer drug doxorubicin hydrochloride, 
and the doxorubicin-loaded AuNPs demonstrated higher 
cytotoxicity towards LN-229 cells, as compared with an 
equal dose of native doxorubicin solution.20 Functionalized 
AuNPs capped with 3-mercaptopropionic acid have also 
been fabricated, and the effects of these AuNPs on two 
leukemia cell lines, adriamycin-sensitive K562 cells and 
adriamycin-resistant K562/A02 cells, have been assayed.21 
Guo et al demonstrated that these functionalized AuNPs 
could increase the hydrophobicity of both cell suspensions, 
greatly decrease the peak potential of both cell lines, and 
facilitate the cellular uptake of the anticancer drug As2O3 into 
K562 leukemia cells.21 Thus, AuNPs can inhibit the function 
of P-glycoprotein to improve the relevant drug accumulation 
in drug-resistant cancer cells and enhance the cytotoxicity 
suppression of As2O3. Chen et al reported the intracellular 
accumulation of EGCG-conjugated AuNPs was due to 
AuNP-mediated endocytosis.22 In our previous report,9 we 
investigated the mechanism of EGCG- and pNG-mediated 
cell apoptosis. We showed that MBT-2 cells treated with 
EGCG or pNG were arrested in the S phase of the cell cycle. 
Bcl-XL, Bad, and Bax are likely connected with EGCG- and 
pNG-mediated MBT-2 cell apoptosis. The pNG showed 
more arrest in the S phase than the growth inhibition in the 
antiapoptoic protein BcL-XL. Improvement in cytotoxicity of 
EGCG/pNG may be attributed to the greater uptake potential 
of pNG by endocytosis or enhanced retention permeability, as 
compared to native EGCG.22,23 The increase in cytotoxicity of 
EGCG/pNG may be due to the enrichment in the internalized 
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Figure 5 Cell viability of MBT-2 cells treated with EGCG and/or pNG at different concentrations over 24 and 48 hours. 
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EGCG conjugate by an endocytosis mechanism, as compared 
to the passive diffusion mechanism of native EGCG.
In vivo antitumor activity of EGCG-pNG
We tested the efficacy of EGCG-pNG to inhibit MBT-2 
tumor growth in vivo in a C3H/He mouse model. The EGCG 
and EGCG-pNG conjugates (pretreated or treated groups) 
were orally or intraperitoneally administered to assess their 
antitumor activities in vivo (Figure 6). Our results revealed 
that tumor-volume ratio was reduced in mice receiving either 
EGCG alone or receiving EGCG-pNG in both the pretreated 
or treated groups (Figure 6A). EGCG and EGCG-pNG 
both demonstrated significant antitumor effects in terms of 
tumor-double time compared to the control group, which 
showed 2.7–9.84 days (Figure 6B). More importantly, 
tumor volume in the EGCG-pNG group was significantly 
less compared with that in the control group (P , 0.05). 
A reduction in angiogenesis and tumor volume was also 
observed (Figure 6C). Mice harboring MBT-2 tumors treated 
with EGCG-pNG developed less edema than mice treated 
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Figure 6 Growth inhibition effects of EGCG and in combination with pNG in a murine MBT-2 subcutaneous tumor model: (A) tumor-volume ratio in the mice was detected 
individually following treatment by feeding 2 mg/mouse EGCG or 2 mg/mouse EGCG-pNG (23:2.5) via an oral route (ig) and intaperitonially (ip); (B) tumor-volume double 
time indicating tumor volumes in mice receiving the different drugs (control, EGCG, and EGCG-pNG) at day 29; (C) photographs and histology (H&E staining, 40×) of excised 
tumors from mice. Pictures of tumors show engorgement of tumor vessels in the control group that are larger than the EGCG and EGCG-pNG groups. The H&E-staining 
histology of the tumor mass shows more vessels in the cross-sectional view in the control compared to the other groups. 
Notes: Black line, 1 cm; black arrows, tumor vessels; scale bar, 25 µm. 
Abbreviations: EGCG, epigallocatechin-3-gallate; H&E, hematoxylin and eosin; pNG, physical nanogold.
Control EGCG EGCG/pNGs
C
with EGCG or control only. Less fluid accumulation in 
the peritoneal cavity was observed in EGCG-pNG-treated 
samples compared with the control and EGCG samples. As 
the size of the tumors was suppressed over 29 days after 
repeated oral administration in contrast to free EGCG, it 
was confirmed that EGCG-pNG had significant antitumor 
activities (Figure 6C).
The anticancer activity of EGCG-pNG was investigated 
in  C3H/HeN  mice  subcutaneously  implanted  with 
MBT-2 murine bladder tumor cells. EGCG-pNG was 
confirmed to inhibit tumor cell growth by means of cell 
apoptosis.9 The mechanism by which EGCG-pNG mediated 
tumor apoptosis was demonstrated to involve activation 
of the caspase cascade, via the Bcl-family proteins, of 
the mitochondrial pathway. Additionally, the mechanism 
by which tumors were suppressed following injection of 
EGCG-pNG directly into the tumor site was determined to 
be through downregulation of vascular endothelial growth 
factor, whereas the effect following oral administration of 
EGCG was through reversing immune suppression upon 
cancer progression. The prepared EGCG-pNG was confirmed 
to be more effective than free EGCG in inhibiting bladder 
tumors in the mouse model. Mukherjee et al24 reported that 
AuNPs can interact specifically to bind vascular permeability 
factor/vascular endothelial growth factor and basic fibroblast 
growth factor, two endothelial cell mitogens and mediators 
of angiogenesis, resulting in inhibition of endothelial/
fibroblast cell proliferation in vitro, induced permeability, 
and angiogenesis in vivo.
Because metal poisoning is associated with renal and 
hepatic toxicities, we determined the effect of nanogold and 
EGCG-pNG administration on liver and renal functions. 
Normal mice were given the same dose of nanogold and 
EGCG-AuNPs as in the mouse tumor model for 7 consecutive 
days. On day 8, the mice were killed and serum was 
collected. There were no significant differences between 
serum levels of creatinine, blood urea nitrogen, bilirubin 
alkaline phosphatase, alanine aminotransferase, or aspartate 
aminotransferase between the EGCG-pNG or nanogold-
treated and untreated control animals (data not shown).
Physical nanogold has been extensively used for a variety 
of biomedical applications and has been employed not only 
as a targeted contrast agent but as scaffolding for cancer 
drug delivery, a transfection agent for gene therapy, and 
an intrinsic antineoplastic agent.25 Portney et al employed 
a cowpea mosaic virus to form NG-CPMV hybrids that 
were used to generate fluorescence for image enhancement 
in MRI.26 Zheng et al demonstrated the utility of ferritin 
bioconjugated nanogold for biomedical detection via surface 
plasmon resonance.27 Mandal and colleagues also reported 
the use of AuNPs chemically cross-linked to carrier peptides 
for directed subcellular localization in osteosarcoma.28 In this 
current study, we presented nanogold hybrid self-assembly 
via ultrasound homogenization and showed that pNG could 
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be successfully employed to deliver EGCG for prolonged 
antitumor and antioxidant activity.
Conclusion
We reported that size-controlled EGCG-pNG particles 
exhibited stability over a wide range of lower pH levels, 
and thus could adapt to gastric digestion. Furthermore, we 
have demonstrated the applicability of these nanoparticles 
as carriers for the delivery of anticancer drugs to enhance 
antioxidant activity and antitumorigenesis. EGCG-pNG 
particles showed great potential for the creation of drug-
delivery systems, as their stability and low toxicity offers 
many possibilities for further developing the formulation of 
EGCG for medical applications.
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